Concordia Healthcare completed the acquisition of Amdipharm Mercury from Cinven for $3.5bn.

Concordia Healthcare, a British multinational pharmaceutical company, completed the acquisition of Amdipharm Mercury, a provider of pharmaceutical and healthcare products, from Cinven, a private equity firm, for $3.5bn. "This acquisition is a key milestone and pivotal turning point in Concordia's strategy, which gives us the platform to take our business to the next level. We are not only acquiring products and commercial infrastructure, but a seasoned management team who has done a fantastic job of building a solid and successful international pharma operation," Mark Thompson, Concordia Chairman and CEO.